Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. [electronic resource]
Producer: 20121211Description: 948-52 p. digitalISSN:- 1096-8652
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Combined Modality Therapy
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Maintenance Chemotherapy
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Multiple Myeloma -- drug therapy
- Peripheral Blood Stem Cell Transplantation
- Proportional Hazards Models
- Remission Induction
- Thalidomide -- administration & dosage
- Transplantation, Autologous
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.